A new publication in the prestigious Lancet Psychiatry seems to provide new evidence for the benefits of long-term antipsychotic maintenance treatment in schizophrenia (Hui et al., Lancet Psychiatry 2018). On closer inspection, however, the paper confuses more than it provides new insights.

Andrea Cipriani from the University of Oxford and colleagues have recently published the largest and most comprehensive meta-analysis of the efficacy of antidepressants in the Lancet. The paper is worth dealing with more intensively.

Work with me at the Central Institute of Mental Health (CIMH) in Mannheim and build with me the future of psychiatry.

The company, which I founded with my sons Nikolaj and Philipp, Brainfoods GmbH, has just launched pre sales of our first three products, Mindme® Drinks.

Miner and colleagues from Stanford University believe that machine psychotherapists based on artificial intelligence could revolutionize mental health care.

The Westdeutscher Rundfunk (WDR) on October 8th and 9th, 2017, broadcasted an interesting feature on the "new paths of psychiatry", which contains many statements I made during an interview on the future of psychopharmacology.

The interesting new antipsychotic compound cariprazine was recently approved by the European Medicines Agency (EMA). Its launch in Germany will be a new touchstone for the German Act on the Reform of the Market for Medicinal Products (AMNOG).

In patients with cancer and agitated delirium in palliative care, haloperidol + lorazepam was significantly more efficacious than haloperidol + placebo.

Two recent articles in the prestigious JAMA journals highlight the importance of spirituality for medicine.

The Lancet Commission "Dementia Prevention, Intervention and Care" suggests that one third of dementia cases can be prevented through change of lifestyle.